Vasonatrin Peptide (VNP) TFA 是心钠素 (ANP) 和C型利钠肽 (CNP) 的嵌合体。Vasonatrin Peptide TFA 具有 CNP 的静脉扩张作用、ANP 的利尿作用以及与 ANP 或 CNP 无关的独特的动脉血管扩张作用。Vasonatrin Peptide TFA 通过 cGMP-PKG 信号通路抑制内质网应激对糖尿病心脏缺血再灌注损伤的保护作用。
Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway[1][2][3].
Vasonatrin Peptide (VNP) markedly enhances adiponectin mRNA expression, as well as protein secretion, however, suppresses IL-6 production in mature adipocytes. In addition, VNP significantly increases the intracellular levels of cGMP. The effects of VNP are mimicked by 8-br-cGMP, whereas inhibits by HS-142-1, or KT-5823[2].
Vasonatrin peptide (100 μg/kg; i.v. ; 10 min before reperfusion) attenuates myocardial ischemia-reperfusion injury in diabetic rats[3].
[1]. Wei CM, et al. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest. 1993;92(4):2048-2052.
[2]. Chen BY, et al. Vasonatrin peptide, a new regulator of adiponectin and interleukin-6 production in adipocytes. J Endocrinol Invest. 2011;34(10):742-746.
[3]. Shi Z, et al. Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms. Am J Physiol Heart Circ Physiol. 2015;308(4):H281-H290.
动态评分
0.0